New ALS drug trial hopes to slow disease progression
NCT ID NCT07410806
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This clinical trial is testing an oral drug called NUZ-001 in 160 people with ALS. Participants take the drug or a placebo daily for 36 weeks. The study measures how the disease progresses using a scale of physical function and survival. The goal is to see if NUZ-001 can slow ALS and improve outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
NUZ-001 (oral drug)
What this could lead to
If successful, this could point toward a treatment that slows ALS progression and improves quality of life.
What could go wrong
This is an early-to-mid stage trial with only 160 participants. The drug may not slow the disease or could cause side effects like liver issues.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS (ALS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Healey Center for ALS at Massachusetts General Hospital
Boston, Massachusetts, 02114, United States